Health Care

Brief Insight about New Clinical Trial of Glioblastoma

11:20:00 PM John Evans 0 Comments

Malignant brain tumors, also described as gliomas, meningiomas, and schwannomas all have an overall incidence of 4.5 per 100,000 of the population. The disease may cause central nervous system changes by invading and destroying tissues as well as secondary effects which constitute mainly compression of the brain, cranial nerves, and cerebral vessels or increased intracranial pressure.
Tumors can occur at any age. In adults, incidence is highest between the ages of 40 and 60. The most common types of brain tumors are described as gliomas and meningiomas. These tumors usually occur above the covering of cerebellum tissue and are called supratentorial tumors. Most tumors in children occur before the tender age of 1 or between ages 2 through 12. The most common are astrocytomas, meduloblastomas, ependymomas, and brain stem gliomas. Brain tumors are one of the most common causes of cancer mortality or death in children. In regards to a prospective health insurance applicant with a history of malignant brain tumors, insurers are hesitant about issuing a policy even after complete remission due to risk of possible life threatening complications arising from increased intracranial pressures, coma, respiratory, or cardiac arrest, and brain herniation.

This article was intended to assist applicants diagnosed with a malignant brain tumor in obtaining an approval for a health insurance policy in the individual private healthcare marketplace. Most insurers will not consider issuing and placing a policy if a malignant tumor was diagnosed within a prior 10 year interval. Some carriers will consider the case contingent on answers received through screening and also if the respective tumor was benign having received medical clearance within the prior 2 years. The following are questions that are specifically asked upon submission of a health insurance application and useful tips to obtain an affirmative underwriting decision or at very least prepare a prospective applicant to apply for a plan which would be approved.

A new clinical trial for Glioblastoma Multiforme (GBM) is proven helpful for cure of primary malignant brain tumor. At the present, there exists no curative treatment and standard therapy only affords a modest, though important, benefit. Immunotherapies, like those to be used in SEJ, are a promising new field of study and have already shown to have some efficacy against other types of cancer.

An activated white blood cell can be deactivated by your body’s immune checkpoints. These inhibitory pathways are there to modulate the immune system’s response, so as to prevent collateral damage to your body. They can also be used by cancer cells to shut the white blood cells that would otherwise attack it. GBM cells are particularly effective at doing this: they are able to secrete several systemic factors which decrease the responsiveness of the body’s immune system and its white blood cells.

You Might Also Like